Leerink Partnrs Increases Earnings Estimates for Exelixis

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Leerink Partnrs raised their FY2026 earnings per share (EPS) estimates for Exelixis in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will earn $2.56 per share for the year, up from their previous estimate of $2.54. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

Several other equities research analysts have also weighed in on EXEL. Truist Financial raised their price objective on Exelixis from $42.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. UBS Group lifted their price target on Exelixis from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. JMP Securities restated a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. BMO Capital Markets cut shares of Exelixis from an "outperform" rating to a "market perform" rating and raised their target price for the stock from $36.00 to $40.00 in a report on Friday, December 20th. Finally, Stephens reaffirmed an "equal weight" rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Exelixis currently has an average rating of "Moderate Buy" and an average price target of $37.59.

Remove Ads

Exelixis Stock Performance

Shares of NASDAQ:EXEL traded down $0.36 during trading hours on Monday, hitting $36.68. 2,342,361 shares of the company's stock traded hands, compared to its average volume of 2,146,256. The company's fifty day simple moving average is $35.86 and its two-hundred day simple moving average is $33.51. Exelixis has a 52 week low of $20.14 and a 52 week high of $40.02. The company has a market cap of $10.27 billion, a price-to-earnings ratio of 20.72, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Insider Buying and Selling

In other news, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 in the last quarter. 2.85% of the stock is currently owned by company insiders.

Institutional Trading of Exelixis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Coppell Advisory Solutions LLC acquired a new stake in Exelixis during the fourth quarter worth about $25,000. Colonial Trust Co SC lifted its holdings in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the last quarter. Principal Securities Inc. boosted its position in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares in the last quarter. USA Financial Formulas bought a new stake in Exelixis during the fourth quarter worth about $32,000. Finally, Kestra Investment Management LLC acquired a new stake in shares of Exelixis during the fourth quarter worth approximately $39,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.